SCHEMBL29347186

SCHEMBL29347186

Cn1c(=O)n(C2CCCCNC2=O)c2ccc(C#CCCCCCC(=O)OC(C)(C)C)cc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 4/20 0.36
CRBN Q96SW2 4/20 0.36
PRKCA P17252 2/20 0.33
PRKCG P05129 1/20 0.33
PRKCB P05771 1/20 0.33
PRKCE Q02156 1/20 0.33
PRKCD Q05655 1/20 0.33
CNR1 P21554 1/20 0.32
ITGB1 P05556 1/20 0.32
ITGA4 P13612 1/20 0.32
BACE1 P56817 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
CCR2 P41597 3/20 0.30
GABRA1 P14867 1/20 0.30
GABRG2 P18507 1/20 0.30
GABRB3 P28472 1/20 0.30
GABRA5 P31644 1/20 0.30
GABRA3 P34903 1/20 0.30
GABRA2 P47869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29347187 0.88 DDB1 (0.44) DDB1CRBNPRKCAPRKCGPRKCB
SCHEMBL29347152 0.84 HTR4 (0.32) DDB1CRBN
SCHEMBL31068578 0.78 HTR4 (0.39) DDB1CRBN
SCHEMBL29347155 0.76 HTR4 (0.34) DDB1CRBNCCR2CCR1CCR5
SCHEMBL23842302 0.76 DDB1 (0.49) DDB1CRBN
SCHEMBL22776794 0.76 DDB1 (0.49) DDB1CRBN
SCHEMBL30392222 0.76 DDB1 (0.49) DDB1CRBN
SCHEMBL25123798 0.76 DDB1 (0.49) DDB1CRBN
SCHEMBL25123857 0.76 DDB1 (0.49) DDB1CRBN
SCHEMBL29991318 0.76 DDB1 (0.49) DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2025-12-25 US disclosed
EP-4650348-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR Mitsubishi Tanabe Pharma Corporation (JP) 2025-11-19 EP disclosed
WO-2024150815-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR 田辺三菱製薬株式会社 2024-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR CRBN, CUL1, CBL DDB1 2368/4885CRBN 1/4885PRKCA 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.